Portage Biotech (PRTG) Stock Forecast, Price Target & Predictions
PRTG Stock Forecast
Portage Biotech stock forecast is as follows: an average price target of $4.88 (represents a -7.22% downside from PRTG’s last price of $5.26) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
PRTG Price Target
The average price target for Portage Biotech (PRTG) is $4.88 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $5.25 to $4.50. This represents a potential -7.22% downside from PRTG's last price of $5.26.
PRTG Analyst Ratings
According to 1 Wall Street analysts, Portage Biotech's rating consensus is 'Buy'. The analyst rating breakdown for PRTG stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Portage Biotech Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 01, 2022 | H.C. Wainwright | $5.25 | $1.47 | 257.14% | -0.19% | |
| Nov 30, 2022 | Oppenheimer | $4.50 | $1.49 | 202.01% | -14.45% |
The latest Portage Biotech stock forecast, released on Dec 01, 2022 by H.C. Wainwright company, set a price target of $5.25, which represents a 257.14% increase from the stock price at the time of the forecast ($1.47), and a -0.19% decrease from PRTG last price ($5.26).
Portage Biotech Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $5.26 | $5.26 | $5.26 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Portage Biotech stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Portage Biotech's last price of $5.26. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 30, 2022 | Oppenheimer | Outperform | Outperform | Hold |
Portage Biotech's last stock rating was published by Oppenheimer on Nov 30, 2022. The company gave PRTG a "Outperform" rating, the same as its previous rate.
Portage Biotech Financial Forecast
Portage Biotech Revenue Forecast
| Sep 24 | Jun 24 | |
|---|---|---|
| Revenue | - | - |
| Avg Forecast | - | - |
| High Forecast | - | - |
| Low Forecast | - | - |
| # Analysts | - | - |
| Surprise % | - | - |
Portage Biotech's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PRTG's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Portage Biotech EBITDA Forecast
| Sep 24 | Jun 24 | |
|---|---|---|
| # Analysts | - | - |
| EBITDA | - | - |
| Avg Forecast | - | - |
| High Forecast | - | - |
| Low Forecast | - | - |
| Surprise % | - | - |
undefined analysts predict PRTG's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Portage Biotech's previous annual EBITDA (undefined) of $NaN.
Portage Biotech Net Income Forecast
| Sep 24 | Jun 24 | |
|---|---|---|
| # Analysts | - | - |
| Net Income | - | - |
| Avg Forecast | $1.66M | $1.41M |
| High Forecast | $1.66M | $1.41M |
| Low Forecast | $1.66M | $1.41M |
| Surprise % | - | - |
Portage Biotech's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PRTG's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Portage Biotech SG&A Forecast
| Sep 24 | Jun 24 | |
|---|---|---|
| # Analysts | - | - |
| SG&A | - | - |
| Avg Forecast | - | - |
| High Forecast | - | - |
| Low Forecast | - | - |
| Surprise % | - | - |
Portage Biotech's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to PRTG last annual SG&A of $NaN (undefined).
Portage Biotech EPS Forecast
| Sep 24 | Jun 24 | |
|---|---|---|
| # Analysts | - | - |
| EPS | - | - |
| Avg Forecast | $1.54 | $1.34 |
| High Forecast | $1.54 | $1.34 |
| Low Forecast | $1.54 | $1.34 |
| Surprise % | - | - |
According to undefined Wall Street analysts, Portage Biotech's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PRTG previous annual EPS of $NaN (undefined).
Portage Biotech Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| KROS | Keros Therapeutics | $16.42 | $101.00 | 515.10% | Buy |
| INZY | Inozyme Pharma | $2.92 | $16.00 | 447.95% | Buy |
| AVTE | Aerovate Therapeutics | $2.67 | $13.00 | 386.89% | Hold |
| XFOR | X4 Pharmaceuticals | $0.80 | $3.67 | 358.75% | Buy |
| ABOS | Acumen Pharmaceuticals | $1.78 | $7.00 | 293.26% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.70 | $6.00 | 252.94% | Buy |
| ARVN | Arvinas | $19.00 | $58.50 | 207.89% | Buy |
| CUE | Cue Biopharma | $1.04 | $3.00 | 188.46% | Buy |
| FENC | Fennec Pharmaceuticals | $6.22 | $15.75 | 153.22% | Buy |
| AMLX | Amylyx Pharmaceuticals | $3.87 | $8.25 | 113.18% | Buy |
| DAWN | Day One Biopharmaceuticals | $12.87 | $24.00 | 86.48% | Buy |
| EWTX | Edgewise Therapeutics | $28.74 | $46.25 | 60.93% | Buy |
| BPMC | Blueprint Medicines | $89.40 | $122.60 | 37.14% | Buy |
| HRMY | Harmony Biosciences | $34.20 | $45.33 | 32.54% | Buy |
| JANX | Janux Therapeutics | $54.10 | $70.25 | 29.85% | Buy |
| PRTG | Portage Biotech | $5.26 | $4.88 | -7.22% | Buy |